课题基金 / 基金详情

COVID-19 Variant Supplement - Design and evaluation of novel inhibitors targeting SARS-CoV-2 polymerase to create lead compounds to develop more effective treatments of COVID-19

COVID-19 Variant Supplement - Design and evaluation of novel inhibitors targeting SARS-CoV-2 polymerase to create lead compounds to develop more effective treatments of COVID-19
COVID-19 变异补充剂 - 设计和评估针对 SARS-CoV-2 聚合酶的新型抑制剂，以创建先导化合物，从而开发更有效的 COVID-19 治疗方法
批准号：
443290
负责人：
Ng Kenneth K
金额：
$3.64万
依托单位：
University of Calgary
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2021
资助国家：
加拿大
项目状态：
已结题
起止时间：
2021-02-01 至 2022-02-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=443290&lang=en
关键词：
Antiviral Therapeutics Enzyme Assay Enzyme Inhibitors Medicinal Chemistry Organic Synthesis Rna Polymerase Structure-Based Drug Design X-Ray Crystallography

项目摘要

项目成果

Ng Kenneth K的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes COVID-19 produces a key enzyme, nsp12, essential for replicating the viral genome. In combination with the sequence of nsp12 from SARS-CoV-2, previous studies on closely related
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Design and evaluation of novel inhibitors targeting SARS-CoV-2 polymerase to create lead compounds to develop more effective treatments of COVID-19
  • 批准号：
    422715
  • 项目类别：
    Operating Grants
  • 资助金额：
    $30.31万
  • 财政年份：
    2020
  • 负责人：
    Ng Kenneth K
  • 依托单位：
    University of Calgary
Targeted Delivery of Therapeutics for Prostate Cancer using High-Density Lipoprotein Nanocarriers
  • 批准号：
    182320
  • 项目类别：
    Studentship Programs
  • 资助金额：
    $1.27万
  • 财政年份：
    2009
  • 负责人：
    Ng Kenneth K
  • 依托单位：
    University of Toronto
海外基金